Changes for page Titan Pharmaceuticals

Last modified by Asif Farooqui on 2020/01/06 14:49
From version < 1.5 >
edited by Asif Farooqui
on 2020/01/06 14:47
To version < 2.1 >
edited by Asif Farooqui
on 2020/01/06 14:48
< >
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -4,7 +4,7 @@
4 4  
5 5  = Overview =
6 6  
7 -Titan Pharmaceuticals (TTNP) is a pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. The company's product development programs utilize its proprietary long-term drug delivery platform, ProNeura™, and focus primarily on innovative treatments for select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit.
7 +Titan Pharmaceuticals (TTNP) is a pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. The company's product development programs utilize its proprietary long-term drug delivery platform, ProNeura™, and focus primarily on innovative treatments for select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit.{{footnote}}https://fintel.io/doc/sec-ttnp-titan-pharmaceuticals-10k-2018-april-02-17957{{/footnote}}
8 8  
9 9  Probuphine®, its first product candidate based on the ProNeura platform, was approved by the FDA in May 2016 for the maintenance treatment of opioid dependence in patients who are stable on low to moderate doses of daily sublingual buprenorphine treatment. The company licensed development and commercialization rights of Probuphine for the U.S. and Canadian markets to Braeburn Pharmaceuticals, Inc., or Braeburn.
10 10  
... ... @@ -87,3 +87,5 @@
87 87  The company do not currently have any sales and marketing capability. As its licensee, Braeburn has sole responsibility for sales and marketing of Probuphine within the United States and, through its sublicensee, Knight Pharmaceuticals, Inc., in Canada. Molteni has sole responsibility for the commercialization of Probuphine in the Molteni Territory. The company's current plans are to make similar arrangements for the commercialization of any additional products the company may successfully develop based on its ProNeura technology.
88 88  
89 89  = References =
90 +
91 +{{putFootnotes/}}
This site is funded and maintained by Fintel.io